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Chronic cisplatin treatment promotes
enhanced damage repair and tumor
progression in a mouse model
of lung cancer
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Chemotherapy resistance is a major obstacle in cancer treatment, yet the mechanisms of response to specific
therapies have been largely unexplored in vivo. Employing genetic, genomic, and imaging approaches, we
examined the dynamics of response to a mainstay chemotherapeutic, cisplatin, in multiple mouse models of
human non-small-cell lung cancer (NSCLC). We show that lung tumors initially respond to cisplatin by sensing
DNA damage, undergoing cell cycle arrest, and inducing apoptosis—leading to a significant reduction in tumor
burden. Importantly, we demonstrate that this response does not depend on the tumor suppressor p53 or its
transcriptional target, p21. Prolonged cisplatin treatment promotes the emergence of resistant tumors with
enhanced repair capacity that are cross-resistant to platinum analogs, exhibit advanced histopathology, and
possess an increased frequency of genomic alterations. Cisplatin-resistant tumors express elevated levels of
multiple DNA damage repair and cell cycle arrest-related genes, including p53-inducible protein with a death
domain (Pidd). We demonstrate a novel role for PIDD as a regulator of chemotherapy response in human lung
tumor cells.
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Lung cancer is the leading cause of cancer death in the
United States, with a 5-year survival rate of only ;15%
(American Cancer Society 2007). The majority of patients
with advanced non-small-cell lung cancer (NSCLC) are
treated with combination therapy that includes a plati-
num-based compound. However, only ;30% of patients
with advanced NSCLC respond to this treatment (Socinski
2004). The remaining;70%of patients suffer negative side
effects associated with drug toxicity without the therapeu-
tic benefits of treatment. Among the;30%of patients that
initially respond, most patients eventually develop resis-
tant disease. Therefore, both inherent and acquired drug
resistance are major barriers to successful platinum-based
therapy. Cisplatin [cis-diamminedichloroplatinum(II)] is
one of the most widely employed drugs in cancer therapy.
Its activity as an anti-cancer agent was discovered >40
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years ago (Rosenberg et al. 1969), and it became the first
FDA-approved platinum compound for cancer treatment
in 1978 (Kelland 2007). Cisplatin and platinum-based
analogs like carboplatin are currently used to treat many
malignancies, including lung, ovarian, head and neck,
bladder, and testicular cancer (Socinski 2004). While the
major barriers limiting the use and efficacy of platinum-
based compounds are toxicity and resistance (Kelland
2007), there are currently no established approaches to
identify patients who are likely to respond to cisplatin-
based therapy.
Cisplatin and carboplatin bind DNA to form intrastrand
and interstrand cross-links between purine bases. Plati-
nated adducts distort the DNA helix in a manner that is
recognized by high-mobility group (HMG) proteins and
other proteins involved in the DNA damage response
(Wang and Lippard 2005). These adducts impair replication
and transcription, which can lead to stalled replication
forks and the formation of double-strand breaks. A number
ofDNA repair pathways, includingmismatch repair (MMR)
and nucleotide excision repair (NER), have been implicated
in platinum adduct repair, and, correspondingly, alterations
in these pathways have been implicated in resistance (Wang
and Lippard 2005; Helleday et al. 2008). Other signaling
pathways—such as those involvingNF-kB, c-ABL, JNK, and
p73—have also been implicated in cisplatin response in
vitro (Kharbanda et al. 1995; Gong et al. 1999; Hayakawa
et al. 2004; Mabuchi et al. 2004; Leong et al. 2007).
Multiple mechanisms that mediate intrinsic or acquired
resistance to cisplatin in vitro have been identified (Kelland
2007). Mechanisms that preclude the formation of plati-
num-DNA (Pt-DNA) adducts include decreased import,
increased detoxification, and increased efflux (Hall et al.
2008). For example, impaired uptake of cisplatin due to
down-regulationof the copper-transporter 1 (CTR1) protein
has been demonstrated in ovarian cancer (Ishida et al. 2002;
Holzer et al. 2006). Increased detoxification by conjugation
of cisplatin to glutathione, coupled with increased export,
has also been documented in ovarian cancer cell lines
derived from the same patient before and after drug re-
sistance (Lewis et al. 1988). However, numerous gene
expression studies have failed to identify a single trans-
porter that is altered universally in cisplatin-resistant cell
lines. It is therefore likely that multiple genes involved in
import, detoxification, and efflux can be involved in clin-
ically relevant resistance. Tissue specificity of transporter
expression may also impact the mechanisms of resistance
in different tumor types (Bando et al. 1998).
Cisplatin resistance can also occur through enhanced
DNA damage repair. NER is thought to be the predom-
inant repair pathway for Pt-DNA adducts. The marked
sensitivity of testicular cancer to cisplatin may be due to
intrinsically lower levels of the NER pathway proteins
ERCC1 and XPA (Welsh et al. 2004). Additionally, in-
creased expression of ERCC1 in ovarian tumors and
cancer cell lines has been associated with cisplatin re-
sistance (Dabholkar et al. 1994; Selvakumaran et al.
2003). Recent clinical trials suggest that patients with
tumors with low ERCC1 levels benefit preferentially
from cisplatin-based chemotherapy (Olaussen et al.
2006). However, very few DNA repair genes have been
functionally validated in vivo.
Finally, the role of the tumor suppressor p53 in mediat-
ing cisplatin response remains controversial and appears to
be cell type-dependent. In some cell lines, p53mutation is
associated with cisplatin resistance (Perego et al. 1996).
However, in other cell lines, loss of p53 increases cisplatin
sensitivity (Pestell et al. 2000). Since p53 is mutated in
;50%of humanNSCLCs (Ahrendt et al. 2000; Skaug et al.
2000), elucidating its role in chemoresistance has impor-
tant implications for treatment strategies.
Although much has been learned from studying resis-
tance mechanisms in isolated cell lines, tumors in vivo
encounter drugs in very different conditions. The tumor
microenvironment may provide signals and physical bar-
riers that alter signaling networks and the context inwhich
cells respond to therapy (Olive et al. 2009). The immune
system can also act as a barrier or promoter of tumor
behavior. Finally, drug pharmacodynamics differ in vitro
compared with in vivo. Therefore, a systematic attempt to
model cisplatin response and resistance in vivo may pro-
vide insights that cannot be ascertained from in vitro
studies. Observations in xenograft models first demon-
strated that in vivo chemotherapy resistance mechanisms
were distinct from those in vitro (Teicher et al. 1990). Few
studies have examined the response of autochthonous
tumors to platinum-based therapy in vivo. For example,
responses to several chemotherapy agents, including cis-
platin, were analyzed in mice bearing Brca1/;p53/
mammary tumors (Rottenberg et al. 2007). Interestingly,
these tumors developed resistance to doxorubicin and
docetaxel but not to cisplatin, even after repeated doses.
Thus, there is still a need for in vivo models of inherent
and acquired resistance to platinum agents.
We described previously the development of mouse
models for human lung cancer in which expression of
oncogenic Kras (mutated in ;30% of NSCLCs) is the
initiating event (Jackson et al. 2001; Johnson et al. 2001).
In the LSL-KrasG12D/+ model, Cre-mediated loss of a stop
cassette permits expression of the oncogenic KrasG12D
allele from its endogenous promoter. Mice develop lung
adenomas with 100% penetrance that eventually prog-
ress to high-grade adenocarcinomas. LSL-KrasG12D/+mice
that possess conditional mutant or null alleles of p53
develop lung tumors with a shorter latency and advanced
histopathology compared with mice with wild-type p53
(Jackson et al. 2005).We demonstrated previously a strong
similarity between KrasG12D-initiated lung tumor models
and human NSCLC at the level of gene expression
(Sweet-Cordero et al. 2005). Since early-stage and ad-
vanced NSCLC are frequently treated with platinum
compounds, we investigated the effects of cisplatin treat-
ment on oncogenic KrasG12D-initiated lung tumors.
Results
Short-term response to cisplatin
LSL-KrasG12D/+ mice were treated intraperitoneally (ip)
with a single dose of cisplatin (7 mg/kg) 12–16 wk after
Oliver et al.
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tumor initiation by intranasal Adeno-Cre (AdCre) infec-
tion (higher doses led to death and excessive weight loss in
pilot studies) (Supplemental Fig. S1). Mice were sacrificed
at different time points following cisplatin treatment to
analyze the effects on cell cycle and cell survival in tumors.
As indicated by BrdU (5-bromo-29-deoxyuridine) incorpo-
ration, cisplatin led to a reduction in the number of cells
entering the cell cycle that was maximal 72 h after a single
dose, with full recovery by 120 h (Fig. 1A). In contrast, the
kinetics of the apoptotic response as measured by cleaved
caspase 3 (CC3) staining had two waves of activity that
peaked at 24 and 72 h, and returned to control levels by
120 h after treatment (Fig. 1B). A maximal decrease in
mitotic index was observed 24 h after cisplatin treatment
and persisted through 72 h (Supplemental Fig. S2).
To investigate whether p53 activation mediates apo-
ptosis and cell cycle arrest in response to cisplatin in this
model, we crossed LSL-KrasG12D/+ mice with conditional
Trp53F2-10/F2-10 mice (Jonkers et al. 2001), hereafter re-
ferred to as p53fl/fl. Delivery of AdCre to the lungs of LSL-
KrasG12D/+;p53fl/fl mice leads to simultaneous activation
of oncogenic Kras and loss of p53 function (Jackson et al.
2005). KrasG12D/+ lung tumors null for p53 had signifi-
cantly higher basal proliferation indices than tumors with
wild-type p53 (P < 0.003), while p53 heterozygous lung
tumors had intermediate levels of proliferation (Supple-
mental Fig. S3). However, in response to cisplatin, both
p53 heterozygous and p53-null lung tumors exhibited cell
cycle arrest similar to that seen in KrasG12D/+ tumors
with wild-type p53 (Fig. 1C). The majority of tumors had
significant decreases in BrdU incorporation 72 h after
cisplatin, regardless of p53 status (Supplemental Fig. S4).
While the maximum number of apoptotic cells observed
in KrasG12D/+;p53fl/fl tumors in response to cisplatin was
decreased compared with KrasG12D/+, we detected a sta-
tistically significant increase in both cases (Fig. 1B,D).
Thus, cell cycle arrest induced by cisplatin is not de-
pendent on p53 in this model, and apoptosis is at least
partially p53-independent as well. We confirmed the lack
of dependence on p53 for cell cycle arrest in this model by
crossing LSL-KrasG12D/+mice tomice lacking a functional
allele of p21 (Brugarolas et al. 1995). KrasG12D/+; p21/
lung tumors had similar cell cycle arrest and apoptosis
profiles in response to cisplatin compared with controls
Figure 1. Cisplatin induces cell cycle arrest and cell death in KrasG12D-initiated lung tumors, independently of p53 activity. (A)
Number of BrdU-positive cells per lung tumor area from LSL-KrasG12D/+ mice treated with a single dose (7 mg/kg body weight) of
cisplatin and analyzed 0–120 h later. (B) Number of CC3-positive cells per lung tumor area, as in A. (C) Number of BrdU-positive cells
per lung tumor area from LSL-KrasG12D/+ mice either heterozygous or homozygous for the p53fl/fl allele, treated as in A. (D) Number of
CC3-positive cells per lung tumor area from LSL-KrasG12D/+ mice either heterozygous or homozygous for the p53flfl allele, treated as in
A. In A–D, number of tumors analyzed is shown for each bar. Error bars represent standard error of the mean (SEM). Significant changes
compared with control are indicated by (*) P < 0.04, (**) P < 0.006, or (***) P < 0.0001. (E–L) PBS-treated lung tumors (E,G,I,K) or
cisplatin-treated lung tumors (F,H,J,L) stained with Pt-1,2-d(GpG) antibody (8 h) (E,F), g-H2AX antibody (24 h) (G,H), anti-phospho Chk1
(Ser345) antibody (12 h) (I,J), or anti-phospho Chk2 (Thr68) antibody (12 h) (K,L).
Cisplatin resistance in lung cancer
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(Supplemental Fig. S5). Taken together, these data suggest
that cisplatin response in vivo is not dependent on the
p53–p21 pathway.
To investigate the kinetics of cisplatin adduct formation
and DNA damage signaling at a cellular level, we analyzed
cisplatin-treated tumors for the presence of Pt-DNA ad-
ducts using a Pt-1,2-d(GpG) intrastrand cross-link-specific
monoclonal antibody (Liedert et al. 2006). This antibody
recognizes the most frequently occurring adduct formed
by cisplatin, which is associated with its cytotoxicity and
anti-cancer activity (Liedert et al. 2006; Dzagnidze et al.
2007). Pt-DNA adducts were detected in the lung as early
as 3 h after a single dose of cisplatin (Fig. 1E,F; data not
shown). Platinum adduct formation can cause stalling of
replication forks, which leads to collapse and the genera-
tion of DNA double-strand breaks (Henry-Mowatt et al.
2003). This leads to activation of checkpoint kinases ATM
and ATR, and their downstream substrates, Chk2 and
Chk1, which recruit other repair proteins to sites of
damaged DNA (Pabla et al. 2008). The phosphorylated
form of the histone variant H2AX (g-H2AX) is a critical
component of this repair complex, and thus can be used as
a marker of DNA damage signaling. In cisplatin-treated
KrasG12D/+ tumors, we detected g-H2AX 4 h (the earliest
time point examined) after cisplatin treatment, with
maximal staining 12–24 h following treatment (Fig.
1G,H; Supplemental Fig. S6; data not shown). Basal phos-
phorylation of the checkpoint kinase Chk2 (Thr68) was
detected in untreated tumors, and increased phosphoryla-
tion of both Chk1 (Ser345) and Chk2 (Thr68) was clearly
evident after cisplatin treatment (Fig. 1I–L). Taken to-
gether, these data demonstrate that tumors sense DNA
damage in response to cisplatin within 4 h, and respond by
cell cycle arrest and cell death associated with activation
of both Chk1 and Chk2. In KrasG12D/+;p53fl/fl lung tumors
analyzed 4–24 h after a single dose of cisplatin, we did not
detect obvious differences in DNA damage signaling
compared with p53 wild-type tumors (Supplemental Fig.
S7). We observed very few tumors with patterns of BrdU or
g-H2AX staining that deviated significantly from themean
at the indicated time points, suggesting that most tumors
initially respond to cisplatin-induced DNA damage in this
model (Supplemental Fig. S4; data not shown).
Long-term response to cisplatin
To analyze the long-term effects of cisplatin therapy on
KrasG12D-initiated lung tumors, we treated mice 12 wk
following AdCre infection with cisplatin once a week for
2 wk, followed by a 2-wk rest period to allow recovery
from toxicity, and repeated this regimen for a total of four
doses of cisplatin (Fig. 2A, Group 3). Tumor response was
measured by determining the ratio of tumor area to total
lung area (TA/LA) in histological sections. Treatment
with cisplatin significantly reduced tumor burden in the
treated G3 group (n = 8) compared with the control G1
mice (n = 7) (P < 0.0002) (Fig. 2B–D).
To determine whether this response was dependent on
intact p53, we treated LSL-KrasG12D/+;p53fl/fl mice with
a similar treatment regimen. Upon sacrifice, the basal
tumor volume in untreated LSL-KrasG12D/+;p53fl/fl mice
wasmuch greater than thosewithwild-type p53. However,
despite this increase in volume, LSL-KrasG12D/+;p53fl/fl
mice treated with cisplatin (n = 11) also had a significant
reduction in tumor burden compared with controls (n = 10)
(P < 0.0001), again demonstrating that wild-type p53 is not
required for response to cisplatin (Fig. 2B,E,F).
Using another cohort of LSL-KrasG12D/+ and LSL-
KrasG12D/+;p53fl/fl mice, we asked whether the impact of
the four-dose regimen of cisplatin could prolong survival
of tumor-bearing mice. Unexpectedly, despite the signif-
icant reduction in tumor burden in LSL-KrasG12D/+ mice
observed after the treatment regimen (Fig. 2B), there was
no improvement in survival (Fig. 2G). In contrast, LSL-
KrasG12D/+;p53fl/fl mice treated with four doses of cis-
platin survived significantly longer (n = 11) than mice
treated with PBS (n = 8) (P < 0.002) (Fig. 2H). Tumors in
LSL-KrasG12D/+ mice develop much more slowly than
tumors that lack p53, and untreated LSL-KrasG12D/+mice
do not die from their lung tumor burden until 7–13 wk
after treated mice receive the fourth dose of cisplatin—a
considerable time frame for residual treated tumors to
regrow. Indeed, tumor burden at the time of death in LSL-
KrasG12D/+ mice treated with four doses of cisplatin was
not significantly different from control animals (data not
shown). In contrast, KrasG12D/+;p53-null lung tumors de-
velop extremely rapidly, and these tumors typically kill
untreated animals near the time when treated mice are
receiving their fourth and final dose of cisplatin. When we
treated LSL-KrasG12D/+ mice with continuous dosing of
cisplatin beyond four doses, mice experienced a significant
survival benefit (Supplemental Fig. S8). The fact that
treatment with cisplatin significantly prolongs survival
of mice with p53-null lung tumors further demonstrates
that p53 is not required for drug response and therapeutic
benefit. This suggests that loss of p53, while a predictor of
poor prognosis and more aggressive tumors in mice, still
permits therapeutic benefits from cisplatin.
Next, to investigate whether residual KrasG12D/+ tu-
mors present at the end of the treatment regimen were
resistant to cisplatin, we treated a cohort of LSL-
KrasG12D/+ mice as described above with four total doses
of cisplatin or PBS, waited 4 wk, and then treated them
with a final 72-h dose of cisplatin before sacrifice (Fig. 2A,
G2 vs. G4). When both sets of mice received a final dose of
cisplatin, tumors from mice that had received previous
cisplatin treatment no longer demonstrated a significant
reduction in BrdU incorporation like the naı¨ve tumors
(Figs. 1A, 2I), suggesting that the pretreated tumors have
acquired resistance to cisplatin treatment.
Dynamics of tumor response to cisplatin
To gain further insight into the dynamics of cisplatin
response in this model, we employed in vivo micro-
computed tomography (microCT) imaging. LSL-
KrasG12D/+ mice were treated with PBS or cisplatin
according to the regimen described above and imaged
prior to treatment, 5 d after the second dose of cisplatin,
and 10 d after the fourth and final dose of cisplatin. We
Oliver et al.
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focused on tumors whose boundaries could be defined
clearly in multiple scans over time. Untreated KrasG12D/+
lung tumors grew slowly (average tumor volume dou-
bling time of ;35 d), with highly variable growth rates.
Following two doses of cisplatin, most tumors in the LSL-
KrasG12D/+ model showed a reduction in tumor volume
(Fig. 3A–C). During the dosing break (between doses 2 and
3), cisplatin-treated tumors resumed growth, but gener-
ally remained sensitive after the third and fourth doses
(Fig. 3A,B). However, some tumors stopped responding to
Figure 2. Cisplatin treatment significantly reduces lung tumor burden in KrasG12D-initiated lung tumors regardless of p53 activity. (A)
Treatment regimens for groups 1–4 (G1–G4). Mice were infected with AdCre to permit expression of KrasG12D at time 0 (gray arrow).
Cisplatin was given at indicated time points in weeks (black arrows) for each group. (B) Tumor area/total lung area in control (G1)
versus treated (G3) LSL-KrasG12D/+ mice (white bars; [***] P < 0.002) and in LSL-KrasG12D/+;p53fl/fl mice (black bars; [***] P < 0.0001).
(C–F). Representative H&E stains at 23 magnification of PBS-treated (C,E) or cisplatin-treated (D,F) lungs from LSL-KrasG12D/+ mice
(C,D) or LSL-KrasG12D/+;p53fl/fl mice (E,F). (G,H). Kaplan-Meier survival curves of LSL-KrasG12D/+ mice (G) and LSL-KrasG12D/+;p53fl/fl
mice (H) treated with four doses of cisplatin (red) or PBS (black). Black arrows indicate cisplatin treatments at X number of days post-
AdCre infection. For H, cisplatin significantly prolongs survival (P < 0.002). (I) Number of BrdU-positive cells per lung tumor area in
LSL-KrasG12D/+ mice with or without a final 72-h dose of cisplatin ([**] P < 0.009). Error bars represent SEM.
Cisplatin resistance in lung cancer
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the third and fourth doses of cisplatin (Fig. 3A). Thus,
while we cannot rule out that innate resistance occurs in
individual clones within tumors, it does not appear to be
a characteristic of bulk tumors. Importantly, in mice that
received four doses of cisplatin and received a final dose of
cisplatin;6 wk later, treated tumors no longer responded,
again suggesting that tumors become resistant after four
doses of cisplatin (Fig. 3B).
KrasG12D/+;p53-null lung tumors grow much faster
than those with wild-type p53 (doubling time of ;7 d),
and therefore it is more straightforward to observe
a significant impact on tumor growth. Indeed, a single
dose of cisplatin caused a significant reduction in tumor
growth in this model, as observed by microCT (data not
shown). Unlike KrasG12D/+ tumors with wild-type p53,
p53-null tumors did not regress, but progressed despite
therapy (Fig. 3D). In a smaller study, we quantified total
tumor burden by microCT in LSL-KrasG12D/+;p53fl/flmice
treated with PBS or four doses of cisplatin. Cisplatin
treatment clearly impeded tumor growth, but tumors
continued to progress despite therapy (Fig. 3E).
Mechanism of cisplatin resistance in vivo
Previous studies suggest that cisplatin resistance in
human cancer may be complex, as no single factor has
been able to explain resistance in full. In vitro studies
suggest that decreased uptake, increased detoxification,
Figure 3. In vivo microCT imaging reveals lung tumor regression and stasis in response to cisplatin in LSL-KrasG12D/+ mice, and
decelerated growth in LSL-KrasG12D/+;p53fl/fl mice. (A) Tumor volume dynamics of individual cisplatin-treated tumors in LSL-KrasG12D/+
mice. Black arrows on the X-axis indicate cisplatin treatments. Red lines indicate tumors that stopped responding to treatment after
three to four doses. The X-axis indicates days following the first pretreatment microCT scan, which occurred 14 wk post-AdCre
infection. (B) Log2-normalized fold change in tumor volume of individual tumors in PBS-treated (white bars) and cisplatin-treated
(black bars) mice. Tumor volumes were quantified before and after doses 1 and 2 (Dose 1–2), before and after doses 3 and 4 (Dose 3–4),
and before and after one final dose (Final). (C) Representative microCT lung reconstructions before and after two doses of PBS (panels
I,II) or cisplatin (panels III,IV) with individual lung tumors pseudocolored. (D) Tumor volume dynamics of individual cisplatin-treated
tumors in response to cisplatin in LSL-KrasG12D/+;p53fl/fl mice. Black arrows on the X-axis indicate cisplatin treatments. (E) Total lung
tumor volume in LSL-KrasG12D/+;p53fl/fl mice (n = 2 mice per group) treated with four doses of PBS (solid lines with circles) or cisplatin
(dashed lines). Arrows on the X-axis (days following AdCre infection) indicate one dose of PBS or cisplatin.
Oliver et al.
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and increased efflux of platinum from cells may all be
mechanisms of resistance. In addition, platinum adducts
may be more rapidly repaired in resistant tumors. Finally,
tumor cells may use error-prone translesion DNA poly-
merases in order to tolerate higher levels of adducts. To
distinguish among these possibilities, we treated long-
term PBS or cisplatin-treated mice with a final dose of
cisplatin, and stained tumor sections with the antibody to
Pt-1,2-intrastrand DNA cross-links to monitor the kinet-
ics of adduct levels. Strikingly, 24 h after a final dose of
cisplatin, long-term-treated tumors had significantly de-
creased levels of Pt-1,2-d(GpG) adducts compared with
tumors frommice treated previously with PBS (G2 vs. G4)
(Fig. 4A–C), whereas adduct levels in the normal sur-
rounding lung cells were similar (Supplemental Fig. S9).
Tumors that completely lacked adducts at this time point
were found only in lungs from long-term cisplatin-treated
animals. To support this observation, we quantified the
levels of g-H2AX in PBS and cisplatin-treated tumors that
had received a final 24-h dose of cisplatin. We observed
a significant reduction in g-H2AX staining in resistant
tumors (Fig. 4D–F), consistent with the lack of adducts at
this time point. These data suggest that the mechanism
of cisplatin resistance in this model is not mediated by
tolerance of platinum adducts in vivo. However, these
data do not discriminate between resistance mechanisms
in which damage never occurs (i.e., import/detoxifica-
tion/export), or in which damage occurs but is repaired
rapidly. To discriminate between these possibilities, we
used atomic absorption spectroscopy (AAS) to quantify
platinum levels in lysates from individual lung tumors
taken from animals treated with PBS or cisplatin (four
total doses), plus a final dose of cisplatin given at 0, 2, 4,
12, 24, 48, or 72 h before sacrifice. Chronic cisplatin
treatment did not cause a significant decrease in plati-
num levels within tumors at any time point examined
(Supplemental Fig. S10), demonstrating that platinum is
able to enter tumors similarly in naı¨ve and pretreated
tumors. This result suggests that decreased import and/or
rapid efflux are not the driving forces behind cisplatin
resistance in this model.
Increased DNA repair has been proposed as a mecha-
nism of platinum resistance (Martin et al. 2008). We
reasoned that, if rapid repair was occurring, we should
Figure 4. Long-term cisplatin-treated lung
tumors in LSL-KrasG12D/+ mice exhibit en-
hanced adduct repair in response to a final
dose of cisplatin. (A) Representative sensitive
lung tumor section (G2) stained with Pt-1,2-
d(GpG) from long-term PBS-treated mice
given a final 24-h dose of cisplatin. (B) Repre-
sentative resistant tumor section (G4) from
long-term cisplatin-treated mice, treated as in
A. (C) Number of Pt-1,2-d(GpG)-positive cells
per lung tumor area in long-term PBS-treated
(white bar) or cisplatin-treated (black bar)
mice given a final dose of cisplatin and
sacrificed 24 h later ([***] P < 0.0001). (D)
Representative sensitive tumor section (G2)
stained with g-H2AX from long-term PBS-
treated mice given a final 24-h dose of cis-
platin. (E) Representative resistant tumor (G4)
from long-term cisplatin-treated mice, treated
as in D. (F) Number of g-H2AX-positive cells
per lung tumor area in long-term PBS-treated
(white bar) or cisplatin-treated (black bar)
mice given a final dose of cisplatin and
sacrificed 24 h later ([***] P < 0.0001). Error
bars represent SEM. (G–I). Representative
immunofluorescent images of lung tumor
sections stained for nuclei (DAPI) or Pt-1,2-
d(GpG) (Cy3), and an overlay of these images
(Overlay) in mice treated with long-term PBS
(LT PBS) or four doses of cisplatin (LT Cis) and
given a final dose of cisplatin and analyzed
after 0 h (G), 4 h (H), or 24 h (I). The top panels
are 103magnification, and the bottom panels
are higher-magnification zooms. (G) Note
that adducts persist in normal parts of the
lung even after multiple weeks in long-term
cisplatin (LT Cis, 0 h). In H (LT Cis, 4 h,
DAPI), two tumors are separated by a dotted
white line. Approximately 20% of tumors in long-term cisplatin mice had reduced adduct levels as early as 4 h after a final dose of
cisplatin (left tumor) whereas the majority of tumors had similar levels of adducts (right tumor) at this time point.
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detect a difference in the kinetics of Pt-1,2-d(GpG) adduct
formation and, potentially, markers of DNA damage
signaling. To explore this possibility, we treated long-
term PBS and cisplatin-treated mice with a final dose of
cisplatin and examined the kinetics of platinum adducts
at early time points (<24 h) following a final dose of
cisplatin (Fig. 4G). Adduct levels were scored blindly as
absent, low, or high (, +, or ++) on at least 20 tumors per
treatment group. As expected, adducts were not present
in naı¨ve tumors (long-term PBS), but, surprisingly, had
persisted in nontumor lung areas of pretreated animals for
at least 4 wk following their last dose of cisplatin (long-
term cisplatin) (Fig. 4G). At 4 h after a final dose of
cisplatin, 81% of cisplatin-pretreated tumors (21 of 26)
had similar levels of adducts as naı¨ve tumors treated with
cisplatin (Fig. 4H). Thus, the majority of tumors showed
similar levels of Pt-1,2-d(GpG) adducts regardless of
whether or not they had previously received cisplatin.
By 8 h after a final dose of cisplatin, 59% of cisplatin-
pretreated tumors (13 of 22) had similar levels of adducts
as naı¨ve cisplatin-treated tumors (data not shown). By 24
h after a final dose of cisplatin, tumors that completely
lacked adducts were found only in cisplatin-pretreated
tumors (Fig. 4I). These data demonstrate that Pt-1,2-
d(GpG) adducts are present in sensitive and most re-
sistant tumors at early time points, but are cleared more
rapidly in tumors pretreated with cisplatin.
Chk1 and Chk2 are checkpoint kinases that are acti-
vated by DNA damage signals mediated by ATM and
ATR. Therefore, we analyzed Chk1 and Chk2 phosphor-
ylation in long-term cisplatin-treated versus control mice
with or without a final 12-h dose of cisplatin as another
marker of whether cells were experiencing DNA damage.
We observed a clear difference in the dynamics of
phosphorylation of these two DNA damage signaling
proteins. Chk1 phosphorylation occurred in response to
cisplatin in tumors from both naı¨ve and long-term-
treated mice (G1 vs. G2, and G3 vs. G4) (Supplemental
Fig. S11), demonstrating that resistant tumors activate
the DNA damage response, and, thus, that cisplatin is
entering these cells. In contrast, Chk2 phosphorylation
was induced after an initial dose of cisplatin (G1 vs. G2),
and then remained high even in tumors that had not been
given cisplatin for several weeks (G3 in Supplemental Fig.
S11). This finding suggests that these two signaling
pathways may be responding to distinct DNA damage
signals as a result of cisplatin treatment—one that is
transient (Chk1), and another that is persistent (Chk2).
Furthermore, it suggests there is a fundamental difference
in the DNA damage response mechanism in naı¨ve and
long-term cisplatin-treated lung tumors. Taken together,
our data strongly argue that increased DNA damage
repair is the predominant mechanism of cisplatin re-
sistance in vivo in this model.
Cross-resistance to platinum analogs
Cisplatin-resistant tumors in the clinical setting are often
cross-resistant to other platinum analogs. To determine
whether cisplatin-resistant tumors were cross-resistant
to other platinum agents, we treated long-term PBS or
cisplatin-treated tumors with a single dose of carboplatin
(50 mg/kg in saline), and analyzed tumors 24 h later for
the presence of Pt-1,2-d(GpG) adducts and DNA damage
signaling (g-H2AX). Carboplatin induces the same type of
Pt-1,2-d(GpG) cross-links as cisplatin in cells, although at
a slightly reduced frequency (Blommaert et al. 1995).
Indeed, in our studies with carboplatin, staining for this
adduct was less intense compared with a single dose of
cisplatin (7 mg/kg) (data not shown). In long-term cis-
platin-treated tumors, carboplatin produces fewer ad-
ducts (data not shown) and reduced DNA damage signal-
ing, evident by g-H2AX staining compared with naı¨ve
tumors (Supplemental Fig. S12). These data indicate that,
just as encountered in clinical resistance (Wang and
Lippard 2005), cisplatin-resistant tumors in this model
are cross-resistant to other platinum analogs.
Comparative genomic analysis of naı¨ve versus
cisplatin-treated tumors
We performed DNA copy number analysis to identify
potential genomic deletions or amplifications that might
implicate particular genes involved in acquired resis-
tance. LSL-KrasG12D/+ mice were treated with long-term
PBS or cisplatin as described in G1 and G3 (Fig. 2), and
then sacrificed;8 wk after their final dose of cisplatin—a
total of 24–30 wk following tumor induction by AdCre.
DNA was isolated from individually microdissected tu-
mors and subjected to representational oligonucleotide
microarray analysis (ROMA) (Lakshmi et al. 2006). Of 11
long-term PBS-treated lung tumors analyzed, only two
(18%) had detectable whole-chromosomal aberrations (Fig.
5A). This observation is consistent with the low frequency
of DNA copy number changes that we reported previously
in this model using BAC arrays (Sweet-Cordero et al.
2006). In contrast, 19 of 23 long-term cisplatin-treated
tumors (83%) harbored whole-chromosomal aberrations,
including gains and losses of whole chromosomes (Fig. 5B–
H). A subset of tumors was analyzed for copy number
changes with independent methodologies, including Agi-
lent Array CGH, Affymetrix SNP Arrays (Broad Institute,
Cambridge, MA), and Solexa sequencing (Illumina); these
techniques consistently validated thewhole-chromosomal
changes identified by ROMA (data not shown).
Strikingly, histological analysis of a subset of these
tumors revealed that the majority of cisplatin-treated
tumors were higher grade (11 of 14 as Grade 2+, 79%)
compared with untreated tumors (two of 10 as Grade 2+,
20%) (Fig. 5I–L). The only two PBS-treated tumors with
whole-chromosomal changes were also scored blindly as
Grade 2+ tumors, whereas eight PBS-treated tumors with
undetectable copy number changes were scored as low-
grade (Grade 2 or less). Therefore, high-grade tumors are
associated consistently with chromosomal abnormali-
ties, whereas low-grade tumors have apparently normal
DNA copy numbers in this model. These data suggest
that long-term cisplatin treatment selects for and/or
promotes tumor progression accompanied by alterations
in chromosome number.
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Gene expression analysis of cisplatin response
and resistance in vivo
The data presented above suggest that long-term cisplatin
treatment creates tumors that are fundamentally differ-
ent from naı¨ve tumors. To characterize these potential
differences, we performed gene expression analysis to
examine cisplatin response and resistance. First, we
examined the dynamics of gene expression changes in
response to cisplatin using laser capture microdissection
to isolate RNA from individual tumors at 24, 48, and 72 h
after a single dose of cisplatin. We analyzed expression of
p21,Mdm2, Bax, and Bcl2 using real-time PCR. Maximal
differential expression of these genes occurred 72 h after
cisplatin treatment despite the fact that DNA damage
response and cell death occurred earlier (data not shown).
We then performed a more global analysis of gene
expression at the same time point after cisplatin therapy
using microarrays. DNA from individually microdis-
sected lung tumors (n = 49) was analyzed using Affyme-
trix 430A Genechips. Samples from mice treated in the
four groups shown in Figure 2 were included: G1 (n = 13),
G2 (n = 11), G3 (n = 9), and G4 (n = 7), as well as normal
lung (n = 9) (Supplemental Table S1).
To identify cellular pathways altered in cisplatin-
treated tumors, we used gene set enrichment analysis
(GSEA) to identify gene sets representing molecular
pathways with significant enrichment in control versus
resistant tumors (Subramanian et al. 2005). GSEA pro-
vides an enrichment score (ES) that measures the degree
of enrichment of a gene set at the top (highly correlated
with class 1) or bottom (highly correlated with class 2) of
a rank-ordered gene list derived from the data set. A
nominal P-value is used to assess the significance of the
individual ES score. We also used the pathway analysis
tool MetaCore from GeneGO, Inc., to identify cellular
processes significantly enriched between treatment
groups. Pathways are defined in MetaCore as a set of
curated consecutive signals or transformations that have
been confirmed by experimental evidence or inferred
relationships. We focused our analysis on the top-scoring
200 genes in each transition (G2 vs. G1: genes up-
regulated in G2 compared with G1; G1 vs. G2: genes
up-regulated in G1 compared with G2, etc.). Consistent
with our data in Figure 2I, cell cycle and proliferation
pathways were significantly enriched in naı¨ve tumors
compared with tumors treated with a single dose of
cisplatin (G1 vs. G2; six of the top eight enriched
pathways were associated with cell cycle and cell pro-
liferation; false discovery rate [FDR] < 0.05, P < 0.003).
However, cell cycle pathways were not similarly repre-
sented in cisplatin-pretreated tumors before and after
treatment with the same dose (G3 vs. G4, and G4 vs.
G3) (Supplemental Table S2). In addition to changes in
cell cycle, pathways enriched in naı¨ve tumors treated
with a single dose of cisplatin (G2 vs. G1) included those
related to adhesion, transport, and immune response
(FDR < 0.25, P < 0.004). In tumors pretreated with four
doses of cisplatin and treated with a final challenge of
cisplatin, pathways enriched in pretreated tumors (G4 vs.
G3) included those related to cell adhesion, G-protein-
coupled receptor (GPCR) signaling, glutathione metabo-
lism, and p53 signaling, whereas those depleted included
pathways related to immune response and apoptosis/
survival (FDR < 0.25, P < 0.05). Pathways enriched in
cisplatin-pretreated tumors compared with naı¨ve tumors
Figure 5. DNA copy number profiling by ROMA
reveals cisplatin treatment enhances the percentage
of lung tumors from LSL-KrasG12D/+ mice with
whole-chromosomal gains and losses. (A) Represen-
tative genomic profile of lung tumors from PBS-
treated mice. Nine of 11 PBS-treated tumors did
not exhibit genomic changes. (B–H) Representative
genomic profiles of cisplatin-treated tumors with
significant whole-chromosomal DNA copy number
changes. Nineteen of 23 cisplatin-treated tumors
harbored whole-chromosomal changes. The X-axis
indicates chromosomal position from chromosome 1
to 19, and XY chromosomes. The Y-axis indicates
copy number. (I,J) Representative H&E-stained tumor
section from PBS-treated mice with low-grade tumor
histology (203, I), and a higher-magnification panel
from the same tumor (403, J). (K,L) Representative
H&E-stained tumor section from cisplatin-treated
mice with high-grade tumor histology (203, K), and
a higher-magnification panel from the same tumor
(403, L). Note the larger nuclei, more diffuse nuclear
staining, and higher nuclear to cytoplasmic ratio in K
and L compared with I and J.
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(G3 vs. G1) were largely related to immune response
(FDR < 0.25, P < 0.05). When comparing treatment of
naı¨ve tumors to cisplatin-pretreated tumors with a final
dose of cisplatin (G4 vs. G2), pathways enriched in
cisplatin-pretreated tumors included those related to cell
cycle and DNA damage, glutathione and methionine
metabolism, cell adhesion, and cytoskeletal remodel-
ing, among others (FDR < 0.25, P < 0.05) (Supplemental
Table S2).
Glutathione-mediated detoxification of cisplatin has
been implicated previously in resistance, and we vali-
dated that a subset of glutathione-related genes (i.e.,
Mgst2 and GstT2) were up-regulated significantly in pre-
treated tumors (data not shown). Because our data suggest
that the majority of cisplatin-resistant tumors repair
adducts more quickly than naı¨ve tumors, we decided to
further pursue the cell cycle/DNA damage class of genes.
In addition to the enrichment of cell cycle/DNA damage
pathways using GeneGO, GSEA identified a DNA dam-
age response gene set enriched in G2 versus G4 (Fig 6A).
We validated the expression levels of a subset of these
genes by real-time RT–PCR on an independent set of
tumors. Cisplatin-resistant tumors expressed higher
basal levels of some genes (Apex1, Chek2, Rad51, and
Rad52) (Fig. 6B). Other genes were induced to a higher
degree in cisplatin-resistant tumors compared with con-
trols (Lrdd, Cdkn1a [p21], Ercc2, and Rad9) (Fig. 6C).
Together, these data support our observation that cis-
platin-resistant tumors have an enhanced ability to repair
Pt-DNA adducts, and, additionally, they have the capac-
ity to induce expression of genes known to play a role in
multiple DNA repair pathways.
Figure 6. Genes associated with DNA
damage and repair are up-regulated in
cisplatin-resistant lung tumors in vivo.
(A) Enrichment plot of the DNA damage
gene set identified by GSEA and corre-
sponding heat map for G2 versus G4.
Expression level is represented as a gradi-
ent from high (red) to low (blue). (B)
Expression of indicated genes in long-term
PBS (LT PBS) versus long-term cisplatin-
treated (four doses, LT Cis) tumors. (C)
Expression of indicated genes in long-term
PBS (LT PBS) or long-term cisplatin (LT
Cis) tumors treated with a final 72-h dose
of cisplatin (LT PBS + 72 h Cis or LT Cis +
72 h Cis). All genes were analyzed in
triplicate by real-time RT–PCR on six in-
dependent tumors per treatment group.
Expression levels are normalized to b-ac-
tin. (**) P < 0.009; (*) P < 0.05. Error bars
represent SEM.
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p53-induced protein with a death domain (PIDD)
expression induces cisplatin resistance in human
cancer cell lines
Of these genes, Lrdd (Pidd) was notable because it had not
been implicated previously in cisplatin resistance in vivo.
PIDD was identified originally as a target gene of p53,
whose expression promoted apoptosis in p53-null cell
lines (Lin et al. 2000). Subsequently, it was shown that
PIDD is an ;90-kDa protein that is constitutively pro-
cessed into two smaller C-terminal fragments, PIDD-C
and PIDD-CC, by autocatalytic cleavage (Tinel et al.
2007). These fragments participate in different signaling
complexes called PIDDosomes, which can act as prosur-
vival or prodeath signals in response to DNA damage,
depending on the context (Tinel and Tschopp 2004;
Janssens et al. 2005; Tinel et al. 2007; Shulga et al.
2009). More recently, PIDD has been implicated in cell
cycle regulation in the context of DNA damage, partic-
ularly in nonhomologous end-joining (NHEJ) and the
G2/M checkpoint (Shi et al. 2009).
We reasoned that, if PIDD is playing a role in cell cycle
arrest or repair in vivo, it should be induced early after
a final dose of cisplatin in resistant tumors. We isolated an
independent set of tumors from LSL-KrasG12D/+ mice
(G1–G4) that were treated with or without a final 8-h
dose of cisplatin and performed real-time RT–PCR for
Pidd expression. Indeed, Pidd expression was significantly
higher only in tumors pretreated with cisplatin (Fig. 7A).
To examine the potential role of PIDD in cisplatin re-
sponse in vitro, we treated three human NSCLC cell lines
that haveKRASmutations andwild-type P53with various
doses of cisplatin and examined expression of PIDD 24 h
following treatment. In all cell lines examined, cisplatin
treatment led to increased levels of PIDDmRNA (Fig. 7B).
To further investigate the role of PIDD in cisplatin
response, we overexpressed PIDD by infecting cells with
retroviruses carrying C-terminal Flag-tagged PIDDwith a
puromycin resistance cassette and selected cells with
puromycin (Tinel et al. 2007). Overexpression was con-
firmed by Western blotting of nuclear and cytoplasmic
cell lysates, with antibodies directed against Flag and
PIDD (Fig. 7C; data not shown). These data demonstrate
the presence of the autocatalytically cleaved forms of
PIDD (;51 kDa and ;37 kDa), which were both present
in the cytoplasm and also in the nucleus, although at
lower levels (Fig. 7C; data not shown). Expression of PIDD
led to reduced growth rate in each cell line (data not
shown), with a corresponding increase in the percentage
of cells in G1 of the cell cycle (Supplemental Fig S13).
Importantly, in the presence of cisplatin, PIDD expres-
sion led to significantly enhanced cell viability (Fig.
7D,E). Strikingly, in H460 cells, overexpression of PIDD
increased the IC50 by 13-fold to 20-fold (Fig. 7D,E). In
addition, overexpression of PIDD contributed to in-
creased resistance to other DNA-damaging agents, in-
cluding gemcitabine and etoposide (Supplemental Fig.
S14). Because PIDD has been implicated in NF-kB-medi-
ated prosurvival signaling, we analyzed expression of the
NF-kB subunit p65 by Western blot of nuclear and
cytoplasmic cell fractions (Supplemental Fig. S15), but
did not detect basal differences as a result of PIDD
Figure 7. Overexpression of PIDD confers resis-
tance to cisplatin in human NSCLC cell lines. (A)
Expression levels of Pidd mRNA in LSL-
KrasG12D/+ lung tumors treated with PBS or four
total doses of cisplatin, with or without a final 8-h
dose of cisplatin (n = 6 tumors per group). P < 0.01.
Error bars represent SEM. (B) Expression levels of
PIDD mRNA in human NSCLC lines treated
with increasing doses of cisplatin (micromolar)
and harvested 24 h following treatment. The
Y-axis is fold change relative to PBS-treated cells.
Expression levels are normalized to ACTIN. (C)
PIDD overexpression in human NSCLC lines by
Western blot (IB) for Flag, and for Parp to confirm
purity of nuclear/cytoplasmic fractions. Upon
longer exposure, full-length PIDD is apparent in
the cytoplasm, and both PIDD cleavage products
are also present in the nucleus (data not shown).
(D) IC50 values for cisplatin treatment in each
cell line with MSCV Vector or MSCV-PIDD
expression from three independent experiments
performed in triplicate. (E) Representative sur-
vival plots for indicated cell lines expressing
MSCV Vector or MSCV-Pidd treated with 0–200
mM cisplatin (X-axis) and analyzed 48 h later
using CellTiter-Glo cell viability assay. The Y-axis
represents percent of viable cells normalized to
PBS-treated control. Error bars represent standard
deviation.
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overexpression. This does not, however, rule out a role for
PIDD in regulating NF-kB signaling, specifically in re-
sponse to damage. Taken together, the mouse in vivo data
and the human in vitro data support an important role for
PIDD in cisplatin resistance in lung cancer.
Discussion
While molecularly targeted therapies hold promise for
the future of cancer treatment, most patients are cur-
rently treated with cytotoxic agents. Cisplatin is an
example of a widely employed anti-cancer drug about
which we have very little understanding of whether
a given patient will be responsive or resistant to treat-
ment. An improved understanding of the molecular and
genetic basis of cisplatin response and resistance could
significantly impact clinical strategies. Previously, mouse
models of hematopoietic malignancies were successfully
used to study the genetics of chemotherapy response
(Schmitt et al. 2000, 2002). However, few attempts have
been made to model chemotherapy resistance in mouse
models of epithelial cancers. Here we used genetically
engineered mouse models of lung cancer to dissect the
molecular and genetic mechanisms of response and re-
sistance to cisplatin therapy in vivo.
We showed that KrasG12D-initiated lung tumors are
responsive to cisplatin treatment regardless of loss of p53.
Tumors initially respond to cisplatin by sensing damage
and undergoing cell cycle arrest and death, leading to
a significant decrease in tumor burden. We provide
genetic evidence that cisplatin efficacy is independent
of p53 loss and does not require the cdk inhibitor p21.
Indeed, an intact p53–p21 pathway was not required for
cell cycle arrest, apoptosis, inhibition of tumor growth, or
survival benefit in this model. Thus, the KrasG12D/+;p53-
null lung tumor model resembles human lung cancer in
that P53 loss confers a poor prognosis, but it does not
necessarily mean that therapy will not be beneficial (Tsao
et al. 2007). However, even though p53-null tumors
respond to cisplatin, our data suggest that there are
fundamental differences in that response compared with
tumors with wild-type p53. Specifically, p53-null tumors
exhibit reduced apoptosis, and, instead of regressing in
response to cisplatin like p53 wild-type tumors, their
growth was simply impaired. Since most patients with
p53 alterations have point mutations in p53, it will be
important to compare the effects of cisplatin in these
mouse models, which we are currently investigating.
Our studies differ from a recent report that investigated
the response of Brca1/;p53/mouse mammary tumors
to treatment with doxorubicin, docetaxel, and cisplatin.
Tumors in this model acquired resistance to doxorubicin
and docetaxel, which was in part mediated by overexpres-
sion of P-glycoprotein. Notably, cisplatin is not implicated
as a substrate of P-glycoprotein, and Brca1/;p53/
mammary tumors remained sensitive to cisplatin after
multiple rounds of treatment (Rottenberg et al. 2007). We
hypothesize that the discrepancy in these results could be
a consequence of the genetic context of BRCA1 and P53
deficiency, since this combination of genetic alterations
has been associated with cisplatin sensitivity (Bartz et al.
2006). Given that these mammary tumors are defective in
homologous recombination (HR), and that tumors defec-
tive in HR are often sensitive to platinum-based com-
pounds, these studies suggest that HR may be an impor-
tant repair pathway contributing to cisplatin resistance.
Indeed, restoration of wild-type BRCA2 in BRCA2-
mutated tumors has been shown to be an important
mechanism of therapeutic resistance to cisplatin (Edwards
et al. 2008; Sakai et al. 2008). Other genes involved in HR
are also up-regulated in resistant tumors in our model (i.e.,
Rad51, Rad52, and Rad9a). Thus, further studies to test
the involvement of HR in resistance in this model may be
warranted.
Importantly, we found that cisplatin treatment of LSL-
KrasG12D/+ mice selected for tumors with increased
genomic instability that were histologically more ad-
vanced. Two possibilities could explain these results.
First, tumor cells with abnormal karyotypes could be
present prior to chemotherapy, and are selected for by
repeated doses of cisplatin. Alternatively, cisplatin treat-
ment itself may induce DNA damage that is not accu-
rately repaired, leading to chromosomal aberrations. Un-
treated KrasG12D/+ mice can develop higher-grade tumors
with whole-chromosomal changes at low frequency (see
the Results; Sweet-Cordero et al. 2006); thus, it is possible
that cisplatin enhances the survival of these cells, which
can eventually develop into more advanced tumors. In
either case, our data suggest that, in some instances,
treating with chemotherapy can have no survival benefit,
and can actually lead to more advanced tumors—in this
case, with increased chromosomal changes, more ad-
vanced histology, and increased drug resistance. Given
that many human cancers have premalignant stages of
tumor progression, it will be important to investigate
whether treating low-grade tumors with DNA-damaging
agents can facilitate tumor progression. This knowledge
will become more important as the technology to detect
earlier-stage disease advances. Whether treating high-
grade genomically unstable tumors with DNA-damaging
agents can promote further progression, such as metasta-
sis, is not well understood. This model could be used to
investigate this possibility. Notably, the observation that
cisplatin treatment can promote genomic instability may
not have been uncovered using tumor cell linemodels that
have already acquired high levels of genomic instability.
We demonstrate that prolonged cisplatin treatment
leads to resistance in KrasG12D-initiated lung tumors.
Acquired cisplatin resistance appears to be mediated by
mechanisms that inhibit the ability of cisplatin to sustain
adducts on DNA. This result is in agreement with early
work pointing to a critical role of 1,2-intrastrand d(GpG)
cross-links in mediating the anti-cancer activity of cis-
platin (Lippard 1982). Our data strongly suggest that the
most predominant mechanism of resistance in this model
is rapid repair of Pt-DNA adducts, based on the following
observations: (1) Using AAS, both naı¨ve and long-term
cisplatin-treated tumors had similar levels of platinum
following cisplatin treatment, ruling out resistance
mechanisms based on platinum entry/export. (2) Analysis
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of adduct kinetics by immunofluorescence demonstrated
that naı¨ve and long-term cisplatin-treated tumors had
similar levels of adducts early, but that long-term-treated
tumors exhibited an enhanced ability to remove adducts
within 24 h after a final dose of cisplatin. (3) Chk1
phosphorylation was induced in both naı¨ve and cis-
platin-pretreated tumors, suggesting that tumors were
encountering DNA damage. Notably, Chk2 phosphory-
lation was persistent in lung tumors that had been treated
multiple times with cisplatin, but had not received
cisplatin for several weeks. This suggests that high basal
phosphorylation of Chk2 is associated with, and could be
causally involved in, cisplatin resistance, and that dam-
age signaling between naı¨ve and long-term-treated tu-
mors is fundamentally different. (4) Cisplatin-pretreated
tumors induced expression of genes that have been
shown to facilitate DNA repair and resistance (including
Apex1, Chek2, Rad51, and Rad52, which were basally
higher, and Pidd, Cdkn1a [p21], Ercc2, and Rad9, which
were induced to higher levels following treatment) (Furuta
et al. 2002; Bartz et al. 2006; Wagner and Karnitz 2009;
Wang et al. 2009). Together, these data suggest that the
predominant mechanism of acquired resistance in this
model is enhanced damage repair.
While our data suggest that import/export and transle-
sional bypass are not frequent mechanisms of resistance,
our data do not exclude the possibility that factors in
addition to enhanced DNA damage repair may also
contribute to resistance. For example, our gene expres-
sion analysis suggests that changes in glutathione me-
tabolism and immune response may alter drug response.
Furthermore, we observe heterogeneity in adduct forma-
tion in resistant tumors in response to a final challenge of
cisplatin. In particular, a subset of resistant tumors
(;20%) have reduced adduct levels even at early time
points (4 h) post-cisplatin (Fig. 4H). We hypothesize that
detoxification of cisplatin by increased glutathione ex-
pressionmay be involved in reducing adduct formation in
these tumors. This model will be useful for testing the
role of other drug resistance mechanisms in vivo.
Our gene expression data suggested that Pidd induction
correlated with and may play a role in chemotherapy
resistance in vivo. We demonstrate for the first time that
overexpression of PIDD in human lung tumor cells can
facilitate cisplatin resistance. In the context of DNA
damage, PIDD has been implicated previously in apopto-
sis, survival, NHEJ, and the G2/M checkpoint. Further
studies will be necessary to determine whether PIDD-
induced chemoresistance is related to its effects on
prosurvival NF-kB signaling, the cell cycle, and/or DNA
damage arrest and repair. Functional studies will be
necessary to elucidate whether PIDD expression is suffi-
cient to induce chemotherapy resistance in vivo, and
whether inhibition of PIDD function could potentially
have therapeutic applications by synergizing with che-
motherapy treatment.
In summary, we established and characterized a model
system for studying response and acquired resistance to
cisplatin in lung cancer. In vivo treatment with cisplatin
in this model recapitulates important features that are
seen in the treatment of human lung cancer. Specifically,
tumors acquire resistance to cisplatin after prolonged
treatment, and this is associated with cross-resistance
to other platinum analogs. This model will be useful for
comparing the efficacy of novel platinum compounds and
combination therapies, as well as their impact on the
emergence of drug resistance.
Materials and methods
Mouse breeding and drug treatment
Mice were housed in an environmentally controlled room
according to the Committee of Animal Care. All mice were bred
onto a 129svJae background. Mice were infected with 3 3 107
plaque-forming units (PFU) of AdCre (University of Iowa) by
nasal instillation as described previously (Jackson et al. 2001) and
allowed to develop tumors for 12–16 wk prior to cisplatin
treatment. Mice were given freshly prepared cisplatin in PBS at
7 mg/kg body weight ip as indicated (Sigma; prepared from
K2PtCl4 supplied as a gift from Engelhard Corporation, now
BASF) or carboplatin (50 mg/kg body weight in saline; Sigma).
For BrdU labeling experiments, BrdU (Sigma) was injected ip
(30 mg/kg) 24 h prior to sacrifice.
Immunohistochemistry
Antibodies and experimental conditions for immunohistochem-
istry are described in the Supplemental Material.
MicroCT
At indicated time points, mice were scanned for 15 min under
isoflurane anesthesia using a small animal eXplore Locus
microCT (GE Healthcare) at 45-mm resolution, 80 kV, with
450-mA current. Images were acquired and processed using GE
eXplore software.
DNA copy number analysis
LSL-KrasG12D/+ mice were treated with long-term PBS or cis-
platin (four total doses over 2 mo). After the fourth dose of
cisplatin, mice were aged for ;4–8 wk in order to allow residual
tumors to increase in volume. Mice were sacrificed, and in-
dividual lung tumors were microdissected from the lung surface
and snap-frozen. DNAwas isolated from individual lung tumors
and tail samples from the same animal using the Puregene DNA
isolation kit (Gentra Systems). Genomic DNA was phenol-
chloroform-extracted three times and submitted to Cold Spring
Harbor Laboratories for ROMA. Briefly, DNAwas digested using
BglII enzyme, PCR-amplified using universal adaptors and
primers, and labeled with fluorophores Cy3 or Cy5 (Lakshmi
et al. 2006). Tumor and tail samples were hybridized onto
NimbleGen chips containing 85,000 mouse probes. Lung tumor
DNA was compared with tail DNA from the same animal. Raw
array data were processed and normalized according to Lakshmi
et al. (2006). A moving-median algorithm based on a window of
five data points was used to smoothen the normalized data to
visualize copy number gains and losses (Kendall et al. 2007).
Gene expression analysis
Mice were sacrificed by cervical dislocation. Lungs were inflated
with RNAlater (Ambion), removed, and placed in the same solu-
tion. Visible tumors were microdissected and frozen immediately
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on dry ice. Frozen tumor samples were thawed in Trizol solution
(Invitrogen), and then homogenized using first a Kontes pestle
and then a polytron homogenizer. RNA and DNAwere isolated
from Trizol using the manufacturer’s instructions. RNA was
further purified using a Qiagen column. RNA was reverse-
transcribed, linearly amplified, and labeled with biotin prior to
hybridization to oligonucleotide using an Ovation amplification
kit (Nugen). All samples were hybridized to Affymetrix 430A
arrays. For the gene expression trial time course by laser capture,
tumors were isolated from KrasLA2 mice (Johnson et al. 2001).
Microarray expression data were validated on at least six
independent tumors per treatment group by real-time RT–
PCR. RNA was isolated by Trizol as described, and 1 mg of total
RNA was converted to cDNA using iScript cDNA synthesis kit
(Bio-Rad). Real-time RT–PCR was performed using gene-specific
primers and Sybr Green Supermix (Bio-rad) in triplicate on an
iCycler real-time machine (Bio-Rad). Analysis was performed
using iCycler software, and expression values were based on 10-
fold serial dilutions of standards and normalized to Actin levels.
Human and mouse primers are included in the Supplemental
Material.
Statistical analysis
All statistical analyses were performed using Graphpad Prism
5.0. For column statistics to determine P-values, unpaired two-
tailed Student’s t-tests were performed. For survival curves, log-
rank (Mantel-Cox) test was performed. For IC50 analysis, non-
linear fit-log(agonist) versus normalized response (variable slope)
was performed.
Cell culture
Human NSCLC lines (H460, SW1573, and A549) were cultured
according to the American Type Culture Collection. Cells were
infected with retroviruses MSCV-Puro or MSCV-Puro-PIDD
(Tinel and Tschopp 2004) and selected with puromycin. For
viability assays, cells were seeded in triplicate (6 3 103 per well)
in an opaque 96-well plate and treated the next day with
increasing doses of cisplatin (0–200 mM). After 48 h of treatment,
cell viability was measured using CellTiter-Glo (Promega) on
a luminometer. PIDD overexpression was validated by West-
ern blotting using antibodies to Flag (M2 clone, Sigma), PIDD
(Anto-1 clone, Alexis), and PARP1 (46D11, Cell Signaling Tech-
nologies). For nuclear and cytoplasmic fractionations, lysates
were prepared as described in the Supplemental Material.
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